Wu Qiuhua, Zhang Xiaoxia, Qin Meiyun, Shi Danfei, Li Yong
Department of Clinical Laboratory, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou City, Huzhou, 313000, Zhejiang, China.
Department of Pathology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou City, Huzhou, 313000, Zhejiang, China.
Clin Rheumatol. 2025 Apr 25. doi: 10.1007/s10067-025-07448-2.
OBJECTIVE: Rheumatoid arthritis (RA) is a chronic autoimmune disease with complex pathological mechanisms, including immune system dysregulation and chronic inflammation. Recent studies indicate that long non-coding RNAs (LncRNAs) play key roles in immune regulation and have been implicated in the pathogenesis of multiple diseases, including RA and various types of cancer. Understanding the involvement of LncRNAs in RA and their potential transcriptional effects in cancer could provide novel insights into disease mechanisms and therapeutic targets. METHODS: Using the GSE94519 dataset, we analyzed serum LncRNA profiles from RA patients and healthy controls. Differential expression genes (DEGs) were identified using GEO2R, and findings were validated via quantitative polymerase chain reaction (qPCR) in 39 RA and 53 healthy samples. Receiver operating characteristic (ROC) analysis was performed to evaluate diagnostic performance. A pan-cancer analysis of MTRNR2L1 was conducted using TCGA data, with immune infiltration assessed via ssGSEA. RESULTS: RNA143598 was significantly upregulated in RA patients, and qPCR confirmed its diagnostic potential (AUC = 0.77). Pan cancer analysis shows that MTRNR2L1 is highly expressed in glioblastoma (GBM) and lowly expressed in head and neck squamous cell carcinoma (HNSC), with high GBM expression linked to poor prognosis. Immune infiltration analysis showed MTRNR2L1 correlated with CD8 + T cells, macrophages, and dendritic cells in GBM. CONCLUSION: RNA143598 is a promising RA biomarker, and its transcription gene MTRNR2L1 demonstrates potential in cancer prognosis and immune regulation. These findings provide a foundation for future research on targeted therapies for RA and cancer. Key Points • RNA143598 is identified as a significant biomarker for diagnosing rheumatoid arthritis (RA), showing promise for clinical application. • Quantitative PCR validation demonstrates the diagnostic potential of RNA143598, with an area under the curve (AUC) of 0.77. • MTRNR2L1, which is RNA143598 transcribed gene, exhibits differential expression in different cancer types, with high levels associated with poor prognosis in glioblastoma (GBM). • Immune infiltration analysis links MTRNR2L1 expression to the presence of CD8 + T cells, macrophages, and dendritic cells, suggesting its role in immune regulation in GBM.
目的：类风湿关节炎（RA）是一种慢性自身免疫性疾病，其病理机制复杂，包括免疫系统失调和慢性炎症。最近的研究表明，长链非编码RNA（LncRNAs）在免疫调节中起关键作用，并与多种疾病的发病机制有关，包括RA和各种类型的癌症。了解LncRNAs在RA中的作用及其在癌症中的潜在转录效应，可为疾病机制和治疗靶点提供新的见解。 方法：使用GSE94519数据集，我们分析了RA患者和健康对照者的血清LncRNA谱。使用GEO2R鉴定差异表达基因（DEGs），并通过定量聚合酶链反应（qPCR）在39例RA患者和53例健康样本中验证结果。进行受试者操作特征（ROC）分析以评估诊断性能。使用TCGA数据对MTRNR2L1进行泛癌分析，并通过单样本基因集富集分析（ssGSEA）评估免疫浸润情况。 结果：RNA143598在RA患者中显著上调，qPCR证实了其诊断潜力（AUC = 0.77）。泛癌分析表明，MTRNR2L1在胶质母细胞瘤（GBM）中高表达而在头颈部鳞状细胞癌（HNSC）中低表达，GBM中的高表达与不良预后相关。免疫浸润分析显示，MTRNR2L1与GBM中的CD8 + T细胞、巨噬细胞和树突状细胞相关。 结论：RNA143598是一种有前景的RA生物标志物，其转录基因MTRNR2L1在癌症预后和免疫调节方面显示出潜力。这些发现为未来RA和癌症靶向治疗的研究奠定了基础。要点：• RNA143598被鉴定为诊断类风湿关节炎（RA）的重要生物标志物，具有临床应用前景。• 定量PCR验证证明了RNA143598的诊断潜力，曲线下面积（AUC）为0.77。• MTRNR2L1是RNA143598的转录基因，在不同癌症类型中表现出差异表达，胶质母细胞瘤（GBM）中的高表达与不良预后相关。• 免疫浸润分析将MTRNR2L1的表达与CD8 + T细胞、巨噬细胞和树突状细胞的存在联系起来，表明其在GBM免疫调节中的作用。
Clin Rheumatol. 2025-4-25
Int Immunopharmacol. 2024-2-15
Arthritis Res Ther. 2016-10-6
Inflamm Bowel Dis. 2024-5-2
Arthritis Res Ther. 2023-10-16
Front Immunol. 2025-3-20
BMC Med Genomics. 2024-10-8
Cancer Immunol Immunother. 2024-7-2
Brief Bioinform. 2024-5-23
Biomedicines. 2024-4-23
MedComm (2020). 2024-3-10
Zotero 插件